ArticleJournal of virology1997
Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses.
Article in Journal of virology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 158 citations in OpenAlex.
- Classification, functions, evolution, and applications of defective viral genomes.Frontiers in microbiology · 2026Review
- Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties.Viruses · 2021Review
- NF-κB promotes leaky expression of adenovirus genes in a replication-incompetent adenovirus vector.Scientific reports · 2016Article
- Suppression of leaky expression of adenovirus genes by insertion of microRNA-targeted sequences in the replication-incompetent adenovirus vector genome.Molecular therapy. Methods & clinical development · 2014Article
- Prevention of adverse events of interferon γ gene therapy by gene delivery of interferon γ-heparin-binding domain fusion protein in mice.Molecular therapy. Methods & clinical development · 2014Article
- Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes.Advances in cancer research · 2012Review
- Helper-Dependent Adenoviral Vectors.Journal of genetic syndromes & gene therapy · 2011Article
- Generation of cell lines to complement adenovirus vectors using recombination-mediated cassette exchange.BMC biotechnology · 2010Article
- Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells).Cell biology and toxicology · 2010Article
- Does neuronal expression of GDNF effectively protect dopaminergic neurons in a rat model of Parkinson's disease?Gene therapy · 2007Article
- Robust functional gene validation by adenoviral vectors: one-step Escherichia coli-derived recombinant adenoviral genome construction.Gene therapy · 2004Article
- Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease.Gene therapy · 2004Article
- Human adenovirus type 35: nucleotide sequence and vector development.Gene therapy · 2003Article
- Cotransfection of heme oxygenase-1 prevents the acute inflammation elicited by a second adenovirus.Gene therapy · 2003Article
- Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation.Gene therapy · 2003Article
- Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.Gene therapy · 2002Article
- Replication-defective vector based on a chimpanzee adenovirus.Journal of virology · 2001Article
- Role for the adenovirus IVa2 protein in packaging of viral DNA.Journal of virology · 2001Article
- Degenerated pIX-IVa2 adenoviral vector sequences lowers reacquisition of the E1 genes during virus amplification in 293 cells.Gene therapy · 2001Article
- Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes.Journal of virology · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have compared the in vitro and in vivo behaviors of a set of isogenic E1- and E1/E4-defective adenoviruses expressing the lacZ gene of Escherichia coli from the Rous sarcoma virus long terminal repeat. Infection of tumor-derived established cell lines of human origin with the doubly defective adenoviruses resulted in (i) a lower replication of the viral backbone that correlated with reduced levels of E2A-specific RNA and protein, (ii) a significant shutoff of late gene and protein expression, and (iii) no apparent virus-induced cytotoxicity. Independently of the extent of the deletion, the additional inactivation of E4 from the viral backbone therefore drastically disabled the virus in vitro, with no apparent effect on transgene expression. A lacZ-transgenic model was used to compare the different recombinant adenoviruses in the livers of C57BL/6 mice. The immune response to the virally encoded beta-galactosidase was minimal in this model, as infusion of the E1-defective adenovirus resulted in a time course of transgene expression that mimicked that in immunodeficient (nu/nu) mice, with very little inflammation and necrosis in the liver. Administration of a doubly defective adenovirus to the transgenic animals led to long-term extrachromosomal persistence of viral DNA in the liver, with no detectable methylation of CpG dinucleotides. However, transient transgene expression was observed independently of the extent of the E4 deletion, suggesting that the choice of the promoter may be critical to maintain transgene expression from these attenuated adenovirus vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.